Determinants of homocysteine levels in colorectal and breast cancer patients

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 4131-4138

  Ferroni, Patrizia ^a   Palmirotta, R ^a   Martini, F ^a   Riondino, S ^a   Savonarola, A ^a   Spila, A ^a   Ciatti, F ^a   Sini, V ^b   Mariotti, S ^b   Del Monte, G ^c   Roselli, M ^b   Guadagni, F ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c San Raffaele Rocca di Papa Clinical Center   (Italy)

Author keywords

Breast cancer; Colorectal cancer; Homocysteinemia; Inflammation

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYANOCOBALAMIN; FIBRINOGEN; FOLIC ACID; HOMOCYSTEINE; INTERLEUKIN 6; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BREAST CANCER; CANCER PATIENT; CANCER RISK; CELL PROLIFERATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA POLYMORPHISM; FEMALE; FOLIC ACID BLOOD LEVEL; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPERHOMOCYSTEINEMIA; INDEPENDENT VARIABLE; INFLAMMATION; MALE; MULTIVARIATE ANALYSIS; NUTRITIONAL STATUS; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; VITAMIN BLOOD LEVEL;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; INFLAMMATION MEDIATORS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NUTRITIONAL STATUS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 71949114575     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Stipanuk MH: Sulfur amino acid metabolism: pathways for production and removal of homocysteine and cysteine. Annu Rev Nutr 24: 539-577, 2004.
2. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP and Rozen R: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 70: 111-113, 1995.
3. Girelli D, Friso S, Trabetti E, Olivieri O, Russo C, Pessotto R, Faccini G, Pignatti PF, Mazzucco A and Corrocher R: Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood 91: 4158-4163, 1998. (Pubitemid 28261978)
4. Phelip JM, Ducros V, Faucheron JL, Flourie B and Roblin X: Association of hyperhomocysteinemia and folate deficiency with colon tumors in patients with inflammatory bowel disease. Inflamm Bowel Dis 14: 242-248, 2008. (Pubitemid 351288046)
5. Peyrin-Biroulet L, Rodriguez-Gúeant RM, Chamaillard M, Desreumaux P, Xia B, Bronowicki JP, Bigard MA and Gúeant JL: Vascular and cellular stress in inflammatory bowel disease: revisiting the role of homocysteine. Am J Gastroenterol 102: 1108-1115, 2007. (Pubitemid 46698241)
6. Laird PW: The power and the promise of DNA methylation markers. Nat Rev Cancer 3: 253-266, 2003.
7. Goelz SE, Vogelstein B, Hamilton SR and Feinberg AP: Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 228: 187-190, 1985. (Pubitemid 15117274)
8. Das PM and Singal R: DNA methylation and cancer. J Clin Oncol 22: 4632-4642, 2004.
9. Zhu BT: On the mechanism of homocysteine pathophysiology and pathogenesis: a unifying hypothesis. Histol Histopathol 17: 1283-1291, 2002.
10. Ratter F, Gassner C, Shatrov V and Lehmann V: Modulation of tumor necrosis factor-alpha-mediated cytotoxicity by changes of the cellular methylation state: mechanism and in vivo relevance. Int Immunol 11: 519-527, 1999. (Pubitemid 29178999)
11. Bogdanski P, Pupek-Musialik D, Dytfeld J, Lacinski M, Jablecka A and Jakubowski H: Plasma homocysteine is a determinant of tissue necrosis factor-alpha in hypertensive patients. Biomed Pharmacother 62: 360-365, 2008. (Pubitemid 351899101)
12. Sattar N, Crompton P, Cherry L, Kane D, Lowe G and McInnes IB: Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis a double-blind, placebo-controlled study. Arthritis Rheum 56: 831-839, 2007. (Pubitemid 46399431)
13. Wu LL and Wu JT: Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor marker. Clin Chim Acta 322: 21-28, 2002. (Pubitemid 34718058)
14. Lewis MR, Callas PW, Jenny NS and Tracy RP: Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples. Thromb Haemost 86: 1495-1500, 2001.
15. Justenhoven C, Hamann U, Pierl CB, Rabstein S, Pesch B, Harth V, Baisch C, Vollmert C, Illig T, Bruning T, Ko Y and Brauch H: One-carbon metabolism and breast cancer risk: no association of MTHFR, MTR, and TYMS polymorphisms in the GENICA study from Germany. Cancer Epidemiol Biomarkers Prev 14: 3015-3018, 2005.
16. Reljic A, Simundic AM, Topic E, Nikolac N, Justinic D and Stefanovic M: The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and cancer risk: the Croatian case-control study. Clin Biochem 40: 981-985, 2007. (Pubitemid 47301797)
17. Plaschke J, Schwanebeck U, Pistorius S, Saeger HD and Schackert HK: Methylenetetrahydrofolate reductase polymorphisms and risk of sporadic and hereditary colorectal cancer with or without microsatellite instability. Cancer Lett 191: 179-185, 2003. (Pubitemid 36255603)
18. Curtin K, Bigler J, Slattery ML, Caan B, Potter JD and Ulrich CM: MTHFR C677T and A1298C polymorphisms: diet, estrogen, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 13: 285-292, 2004. (Pubitemid 38222562)
19. Battistelli S, Vittoria A, Stefanoni M, Bing C and Roviello F: Total plasma homocysteine and methylenetetrahydrofolate reductase C677T polymorphism in patients with colorectal carcinoma. World J Gastroenterol 12: 6128-6132, 2006. (Pubitemid 44688160)
20. Chen J, Giovannucci E, Kelsey K, Rimm EB, Stampfer MJ, Colditz GA, Spiegelman D, Willett WC and Hunter DJ: A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 56: 4862-4864, 1996. (Pubitemid 26374419)
21. Le Marchand L, Haiman CA, Wilkens LR, Kolonel LN and Henderson BE: MTHFR polymorphisms, diet, HRT, and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 13: 2071-2077, 2004. (Pubitemid 40054300)
22. Beilby J, Ingram D, Hahnel R and Rossi E: Reduced breast cancer risk with increasing serum folate in a case-control study of the C677T genotype of the methylenetetrahydrofolate reductase gene. Eur J Cancer 40: 1250-1254, 2004. (Pubitemid 38526345)
23. Martin DN, Boersma BJ, Howe TM, Goodman JE, Mechanic LE, Chanock SJ and Ambs S: Association of MTHFR gene polymorphisms with breast cancer survival. BMC Cancer 6: 257, 2006.
24. Slattery ML, Potter JD, Samowitz W, Schaffer D and Leppert M: Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 8: 513-518, 1999. (Pubitemid 29270335)
25. Keku T, Millikan R, Worley K, Winkel S, Eaton A, Biscocho L, Martin C and Sandler R: 5,10-Methylenetetrahydrofolate reductase codon 677 and 1298 polymorphisms and colon cancer in African-Americans and whites. Cancer Epidemiol Biomarkers Prev 11: 1611-1621, 2002. (Pubitemid 36020015)
26. Ulrich CM, Curtin K, Potter JD, Bigler J, Caan B and Slattery ML: Polymorphisms in the reduced folate carrier, thymidylafe synthase, or methionine synthase and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 14: 2509-2516, 2005.
27. Le Marchand L, Wilkens LR, Kolonel LN and Henderson BE: The MTHFR C677T polymorphism and colorectal cancer: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 14: 1198-1203, 2005. (Pubitemid 40656467)
28. Gershoni-Baruch R, Dagan E, Israeli D, Kasinetz L, Kadouri E and Friedman E: Association of the C677T polymorphism in the MTHFR gene with breast and/or ovarian cancer risk in Jewish women. Eur J Cancer Dec 36: 2313-2316, 2000. (Pubitemid 30947826)
29. Campbell IG, Baxter SW, Eccles DM and Choong DY: Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer. Breast Cancer Res 4: R14, 2002.
30. Chen J, Gammon MD, Chan W, Palomeque C, Wetmur JG, Kabat GC, Teitelbaum SL, Britton JA, Terry MB, Neugut AI and Santella RM: One-carbon metabolism, MTHFR polymorphisms, and risk of breast cancer. Cancer Res 65: 1606-1614, 2005.
31. Shrubsole MJ, Shu XO, Ruan ZX, Cai Q, Cai H, Niu Q, Gao YT and Zheng W: MTHFR genotypes and breast cancer survival after surgery and chemotherapy: a report from the Shanghai Breast Cancer Study. Breast Cancer Res Treat 91: 73-79, 2005. (Pubitemid 40684940)
32. Shannon B, Gnanasampanthan S, Beilby J and Iacopetta B: A polymorphism in the methylenetetrahydrofolate reductase gene predisposes to colorectal cancers with microsatellite instability. Gut 50: 520-524, 2002. (Pubitemid 34638872)
33. Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet 257: 539-545, 2001.
34. Ardizzoia A, Lissoni P, Brivio F, Tisi E, Perego MS, Grassi MG, Pittalis S, Crispino S, Barni S and Tancini G: Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease. J Biol Regul Homeost Agents 6: 103-107, 1992. (Pubitemid 23000988)
35. Belluco C, Nitti D, Frantz M, Toppan P, Basso D, Plebani M, Lise M and Jessup JM: Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol 7: 133-138, 2000. (Pubitemid 30164682)
36. Ito H and Miki C: Profile of circulating levels of interleukin-1 receptor antagonist and interleukin-6 in colorectal cancer patients. Scand J Gastroenterol 34: 1139-1143, 1999. (Pubitemid 29533774)
37. Ueda T, Shimada E and Urakawa T: Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 29: 423-429, 1994. (Pubitemid 24262709)
38. Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, Imperatore V, Catalano G, Pignatelli C and De Vita F: Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 102: 169-178, 2002. (Pubitemid 34171516)
39. Roselli M, Guadagni F, Martini F, Spila A, Mariotti S, D'Alessandro R, Aloe S, Gazzaniga PP, Basili S, Cosimelli M and Ferroni P: Association between serum carcinoembryonic antigen and endothelial cell adhesion molecules in colorectal cancer. Oncology 65: 132-138, 2003. (Pubitemid 37025974)
40. Li R, Rüttinger D, Li R, Si LS and Wang YL: Analysis of the immunological microenvironment at the tumor site in patients with non-small cell lung cancer. Langenbecks Arc Surg 388: 406-412, 2003. (Pubitemid 37509461)
41. Guadagni F, Ferroni P, Palmirotta R, Portarena I, Formica V and Roselli M: TNF/VEGF cross-talking in chronic inflammation-related cancer initiation and progression: an early target in anticancer therapeutic strategy. In Vivo 21: 147-162, 2007. (Pubitemid 46534267)